Respiratory mucosa vaccine platform with novel coronavirus spike protein as carrier
By using the spike protein of the novel coronavirus as an antigen carrier for a respiratory mucosal vaccine, mice were inoculated via nasal drops. This approach addressed the problem of insufficient immune response at the respiratory mucosa site in existing vaccines, achieving a highly efficient immune response under adjuvant-free conditions.
Patent Information
- Application Number
- CN202511909108.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-12-17
- Publication Date
- 2026-04-03
AI Technical Summary
Existing COVID-19 vaccines are difficult to effectively induce local mucosal immune responses in the respiratory mucosa, and intramuscular injection requires specialized equipment and is costly. Existing respiratory mucosal adjuvants have not been approved for clinical use.
Using the spike protein of SARS-CoV-2 as the antigen carrier for a respiratory mucosal vaccine, mice were inoculated via nasal drops without any adjuvants, which induced the production of respiratory mucosal IgA antibodies and serum IgG antibodies. Furthermore, a fusion protein was constructed by fusing the HA of influenza A virus with the spike protein of SARS-CoV-2 and inserting it into the receptor binding site for inoculation.
Without adjuvant, the production of respiratory mucosal IgA and serum IgG antibodies was successfully induced, enhancing the strength and persistence of the immune response and demonstrating the application potential of the SARS-CoV-2 spike protein as an antigen carrier for respiratory mucosal vaccines.